The company is an award-winning provider of a range of regenerative treatments for pain or injury, priding itself on its comprehensive treatment programs and strong reputation for successful results.

The business has developed an extensive non-surgical treatment program for a specific type of arthritis and provides prolozone therapy and prolotherapy.

The company is now being offered for sale to enable our clients to focus on other, unrelated business interests.

Our clients are open to all types of structured deals, subject to terms.

Offers invited.

Key Highlights

– Wide-ranging and diverse client base, with the company benefitting from a vast number of client video testimonials.

-Operates from rented rooms in a medical centre.

-The popularity of the treatments offered has grown exponentially in recent years, with over 16k people searching the terms online across the UK.

-Scope to increase revenue exponentially through offering franchising opportunities, with external interest having already been expressed by clinic operators in different parts of the country.

– The global joint pain injections market size is expected to grow at a CAGR of circa 7.9%, reaching $10.75bn by 2030.

Financial Highlights

– Turnover of circa £570k with an adjusted EBITDA of £250k.

– Projected turnover of £700k in YE24 with an adjusted EBITDA of £350k.